688253 英诺特
已收盘 04-03 15:00:00
资讯
新帖
简况
每周股票复盘：英诺特（688253）获偏肺病毒检测试剂注册证
证券之星 · 03-08
每周股票复盘：英诺特（688253）获偏肺病毒检测试剂注册证
英诺特最新公告：公司新取得一项产品资质
证券之星 · 03-05
英诺特最新公告：公司新取得一项产品资质
英诺特(688253.SH)2025年度归母净利润1.46亿元 同比下降40.84%
智通财经 · 02-11
英诺特(688253.SH)2025年度归母净利润1.46亿元 同比下降40.84%
英诺特（688253）6764.75万股限售股将于1月28日解禁，占总股本49.38%
证券之星 · 01-28
英诺特（688253）6764.75万股限售股将于1月28日解禁，占总股本49.38%
每周股票复盘：英诺特（688253）49.3834%限售股1月28日上市
证券之星 · 01-25
每周股票复盘：英诺特（688253）49.3834%限售股1月28日上市
英诺特（688253）披露首次公开发行限售股上市流通公告，1月19日股价下跌0.48%
证券之星 · 01-19
英诺特（688253）披露首次公开发行限售股上市流通公告，1月19日股价下跌0.48%
每周股票复盘：英诺特（688253）预计2026年日常关联交易额600万元
证券之星 · 01-18
每周股票复盘：英诺特（688253）预计2026年日常关联交易额600万元
英诺特（688253）披露预计2026年度日常关联交易额度，1月15日股价下跌2.55%
证券之星 · 01-15
英诺特（688253）披露预计2026年度日常关联交易额度，1月15日股价下跌2.55%
每周股票复盘：英诺特（688253）获数字化单分子免疫分析仪资质
证券之星 · 01-11
每周股票复盘：英诺特（688253）获数字化单分子免疫分析仪资质
英诺特（688253）披露近期获得资质情况，1月8日股价上涨2.26%
证券之星 · 01-08
英诺特（688253）披露近期获得资质情况，1月8日股价上涨2.26%
英诺特最新公告：公司近期取得2项产品资质
证券之星 · 01-08
英诺特最新公告：公司近期取得2项产品资质
英诺特：天弘基金投资者于12月9日调研我司
证券之星 · 2025-12-15
英诺特：天弘基金投资者于12月9日调研我司
英诺特（688253）披露近期获得资质情况，12月1日股价下跌1.39%
证券之星 · 2025-12-01
英诺特（688253）披露近期获得资质情况，12月1日股价下跌1.39%
每周股票复盘：英诺特（688253）推股东回馈活动赠iPhone17等
证券之星 · 2025-11-23
每周股票复盘：英诺特（688253）推股东回馈活动赠iPhone17等
每周股票复盘：英诺特（688253）Q3呼吸道产品仍为主要收入来源
证券之星 · 2025-11-16
每周股票复盘：英诺特（688253）Q3呼吸道产品仍为主要收入来源
英诺特（688253）2025年三季报简析：净利润同比下降46.37%，三费占比上升明显
证券之星 · 2025-11-01
英诺特（688253）2025年三季报简析：净利润同比下降46.37%，三费占比上升明显
股市必读：英诺特三季报 - 第三季度单季净利润同比下降84.04%
证券之星 · 2025-10-31
股市必读：英诺特三季报 - 第三季度单季净利润同比下降84.04%
英诺特(688253.SH)发布前三季度业绩，归母净利润1.31亿元，同比下降46.37%
智通财经 · 2025-10-30
英诺特(688253.SH)发布前三季度业绩，归母净利润1.31亿元，同比下降46.37%
英诺特(688253)9月30日股东户数0.8万户，较上期增加10.57%
证券之星 · 2025-10-30
英诺特(688253)9月30日股东户数0.8万户，较上期增加10.57%
每周股票复盘：英诺特（688253）限制性股票归属526,120股上市
证券之星 · 2025-09-28
每周股票复盘：英诺特（688253）限制性股票归属526,120股上市
加载更多
公司概况
公司名称：
北京英诺特生物技术股份有限公司
所属行业：
医药制造业
上市日期：
2022-07-28
主营业务：
北京英诺特生物技术股份有限公司的主营业务是POCT快速诊断产品研发、生产和销售。公司的主要产品是呼吸道系列、优生优育系列、其他试剂系列、POCT诊断仪器。
发行价格：
26.06
{"stockData":{"symbol":"688253","market":"SH","secType":"STK","nameCN":"英诺特","latestPrice":35.13,"timestamp":1775199600000,"preClose":36.07,"halted":0,"volume":1385771,"delay":0,"changeRate":-0.0261,"floatShares":137000000,"shares":137000000,"eps":0.9742,"marketStatus":"已收盘","change":-0.94,"latestTime":"04-03 15:00:00","open":36.34,"high":36.66,"low":35.03,"amount":49184100,"amplitude":0.0452,"askPrice":35.14,"askSize":7,"bidPrice":35.13,"bidSize":0,"shortable":0,"etf":0,"ttmEps":0.9742,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1775525400000},"marketStatusCode":5,"adr":0,"adjPreClose":36.07,"symbolType":"stock_kcb","openAndCloseTimeList":[[1775179800000,1775187000000],[1775192400000,1775199600000]],"highLimit":39.68,"lowLimit":32.46,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":136984316,"isCdr":false,"pbRate":2.37,"roa":"--","peRate":36.060357,"roe":"6.5%","epsLYR":1.81,"committee":0.665738,"marketValue":4812000000,"turnoverRate":0.0101,"status":1,"nextConnectDate":"根据港交所公布的数据，今日已停止北向交易，下一个交易日为北京时间 2026-04-08。","afterMarket":{"amount":0,"volume":0,"close":35.13,"buyVolume":537,"sellVolume":0,"time":1775201637560,"indexStatus":"已收盘 04-03 15:30:00","preClose":36.07},"floatMarketCap":4812000000},"requestUrl":"/m/hq/s/688253","defaultTab":"news","newsList":[{"id":"2617663584","title":"每周股票复盘：英诺特（688253）获偏肺病毒检测试剂注册证","url":"https://stock-news.laohu8.com/highlight/detail?id=2617663584","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617663584?lang=zh_cn&edition=full","pubTime":"2026-03-08 03:09","pubTimestamp":1772910551,"startTime":"0","endTime":"0","summary":"截至2026年3月6日收盘，英诺特报收于34.8元，较上周的36.44元下跌4.5%。本周，英诺特3月2日盘中最高价报36.32元。本周关注点公司公告汇总：英诺特取得偏肺病毒、副流感病毒抗原联合检测试剂盒注册证。公司公告汇总北京英诺特生物技术股份有限公司近期取得1项新产品资质，获批产品为偏肺病毒、副流感病毒抗原联合检测试剂盒，注册证号国械注准20263400444，发证日期为2026年3月3日，有效期至2031年3月2日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030800001095.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688253"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2617951245","title":"英诺特最新公告：公司新取得一项产品资质","url":"https://stock-news.laohu8.com/highlight/detail?id=2617951245","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2617951245?lang=zh_cn&edition=full","pubTime":"2026-03-05 17:07","pubTimestamp":1772701622,"startTime":"0","endTime":"0","summary":"英诺特(688253.SH)公告称，公司近期新取得一项产品资质，为偏肺病毒、副流感病毒抗原联合检测试剂盒（乳胶层析法）的医疗器械注册证。该产品预期用途为用于体外定性检测口咽拭子样本中的偏肺病毒抗原、副流感病毒抗原。上述资质的取得，拓宽了公司产品的种类，进一步提高了公司的市场拓展能力及核心竞争力。但该产品的实际销售受到市场需求、市场竞争以及公司市场推广效果等多种因素影响，利润贡献具有不确定性，尚无法预测上述产品对公司未来经营业绩的影响。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026030500026924.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688253","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2610045989","title":"英诺特(688253.SH)2025年度归母净利润1.46亿元 同比下降40.84%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610045989","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610045989?lang=zh_cn&edition=full","pubTime":"2026-02-11 15:44","pubTimestamp":1770795854,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英诺特(688253.SH)发布2025年度业绩快报，报告期内，公司实现营业总收入4.22亿元，同比下降32.08%;实现归属于母公司所有者的净利润1.46亿元，同比下降40.84%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1404128.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"英诺特(688253.SH)2025年度归母净利润1.46亿元 同比下降40.84%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688253"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606751244","title":"英诺特（688253）6764.75万股限售股将于1月28日解禁，占总股本49.38%","url":"https://stock-news.laohu8.com/highlight/detail?id=2606751244","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606751244?lang=zh_cn&edition=full","pubTime":"2026-01-28 08:13","pubTimestamp":1769559190,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，英诺特于1月28日将有6764.75万股限售股份解禁，为公司追加承诺限售股份上市流通，占公司总股本49.38%。本次解禁后，公司已无限售股份。英诺特主营业务：POCT快速诊断产品研发、生产和销售。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012800007007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688253"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2606232098","title":"每周股票复盘：英诺特（688253）49.3834%限售股1月28日上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2606232098","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606232098?lang=zh_cn&edition=full","pubTime":"2026-01-25 03:18","pubTimestamp":1769282293,"startTime":"0","endTime":"0","summary":"截至2026年1月23日收盘，英诺特报收于35.56元，较上周的35.43元上涨0.37%。本次上市流通的限售股数量为67,647,516股，占公司总股本的49.3834%，上市流通日期为2026年1月28日。上述股东已严格履行股份锁定承诺，保荐机构对本次限售股上市流通无异议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012500001157.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688253","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604251131","title":"英诺特（688253）披露首次公开发行限售股上市流通公告，1月19日股价下跌0.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2604251131","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604251131?lang=zh_cn&edition=full","pubTime":"2026-01-19 22:48","pubTimestamp":1768834096,"startTime":"0","endTime":"0","summary":"截至2026年1月19日收盘，英诺特报收于35.26元，较前一交易日下跌0.48%，最新总市值为48.3亿元。公司近日发布公告称，北京英诺特生物技术股份有限公司首次公开发行限售股将于2026年1月28日上市流通。本次解除限售股份数量为67,647,516股，占公司总股本的49.3834%。限售股股东共5名，包括实际控制人叶逢光、张秀杰及其一致行动人控制的企业和员工持股平台。保荐机构对本次限售股上市流通无异议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011900036082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688253","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2604923724","title":"每周股票复盘：英诺特（688253）预计2026年日常关联交易额600万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2604923724","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2604923724?lang=zh_cn&edition=full","pubTime":"2026-01-18 03:21","pubTimestamp":1768677667,"startTime":"0","endTime":"0","summary":"截至2026年1月16日收盘，英诺特报收于35.43元，较上周的32.03元上涨10.62%。本周关注点公司公告汇总：预计2026年与迁安市兴衡企业发生日常关联交易，总额600万元。预计2026年度与迁安市兴衡企业管理咨询服务有限公司发生采购商品、接受服务及房屋租赁服务等日常关联交易，合计预计金额为600万元，以市场价格为定价依据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011800000843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688253"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2603603902","title":"英诺特（688253）披露预计2026年度日常关联交易额度，1月15日股价下跌2.55%","url":"https://stock-news.laohu8.com/highlight/detail?id=2603603902","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603603902?lang=zh_cn&edition=full","pubTime":"2026-01-15 17:40","pubTimestamp":1768470040,"startTime":"0","endTime":"0","summary":"截至2026年1月15日收盘，英诺特报收于34.76元，较前一交易日下跌2.55%，最新总市值为47.62亿元。公司近日发布公告称，北京英诺特生物技术股份有限公司于2026年1月15日召开第二届董事会第十三次会议，审议通过《关于预计2026年度日常关联交易额度的议案》，关联董事回避表决。公告显示，公司预计2026年度与迁安市兴衡企业管理咨询服务有限公司发生采购商品、接受服务及房屋租赁服务等日常关联交易，合计预计金额为600万元，以市场价格为定价依据。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011500029302.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688253"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2602535147","title":"每周股票复盘：英诺特（688253）获数字化单分子免疫分析仪资质","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535147","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535147?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:55","pubTimestamp":1768071310,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，英诺特报收于32.03元，较上周的30.18元上涨6.13%。本周，英诺特1月9日盘中最高价报32.18元。英诺特当前最新总市值43.88亿元，在医疗器械板块市值排名83/127，在两市A股市值排名3821/5182。上述产品基于单分子阵列检测技术，检测灵敏度达fg级别，可实现多种生物标志物同时检测，有助于神经系统疾病等的超早期诊断。资质的取得有助于提升公司市场拓展能力和核心竞争力。产品实际销售及业绩影响存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000759.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688253"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601039888","title":"英诺特（688253）披露近期获得资质情况，1月8日股价上涨2.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601039888","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601039888?lang=zh_cn&edition=full","pubTime":"2026-01-08 22:24","pubTimestamp":1767882261,"startTime":"0","endTime":"0","summary":"截至2026年1月8日收盘，英诺特报收于31.65元，较前一交易日上涨2.26%，最新总市值为43.36亿元。该股当日开盘30.86元，最高31.86元，最低30.83元，成交额达5880.66万元，换手率为2.7%。公司近日发布关于近期获得资质情况的自愿披露公告。公告显示，北京英诺特生物技术股份有限公司近期取得两项产品资质，分别为数字化单分子免疫分析仪和全自动数字化单分子免疫分析仪，注册证号均为京械注准，有效期至2030年12月30日。产品实际销售及业绩影响存在不确定性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800039006.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688253"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2601522973","title":"英诺特最新公告：公司近期取得2项产品资质","url":"https://stock-news.laohu8.com/highlight/detail?id=2601522973","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601522973?lang=zh_cn&edition=full","pubTime":"2026-01-08 17:27","pubTimestamp":1767864462,"startTime":"0","endTime":"0","summary":"英诺特(688253.SH)公告称，公司近期新取得2项产品资质，包括数字化单分子免疫分析仪和全自动数字化单分子免疫分析仪，均获得京械注准20252221036和京械注准20252221035注册证号，有效期至2030年12月30日。这些产品依托于单分子阵列检测技术，能有效解决低丰度生物标志物检测难题，有望在神经系统疾病早期诊断中发挥重要作用。然而，实际销售情况受多种因素影响，利润贡献具有不确定性，对公司未来经营业绩的影响尚无法预测。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010800027575.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688253"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2591612644","title":"英诺特：天弘基金投资者于12月9日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2591612644","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591612644?lang=zh_cn&edition=full","pubTime":"2025-12-15 17:43","pubTimestamp":1765791783,"startTime":"0","endTime":"0","summary":"证券之星消息，2025年12月15日英诺特发布公告称天弘基金吕俏 刘盟盟 李佳豪 钟颖 张秀磊于2025年12月9日调研我司。公司对相关项目的研判及决策较为审慎，具体进展情况公司将按照相关监管规则及时履行信息披露义务。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500022173.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688253"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2588077550","title":"英诺特（688253）披露近期获得资质情况，12月1日股价下跌1.39%","url":"https://stock-news.laohu8.com/highlight/detail?id=2588077550","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588077550?lang=zh_cn&edition=full","pubTime":"2025-12-01 22:26","pubTimestamp":1764599165,"startTime":"0","endTime":"0","summary":"截至2025年12月1日收盘，英诺特报收于34.06元，较前一交易日下跌1.39%，最新总市值为46.66亿元。该股当日开盘34.54元，最高35.11元，最低33.93元，成交额达8292.61万元，换手率为3.49%。公司近日发布关于近期获得资质情况的自愿披露公告。公告称，北京英诺特生物技术股份有限公司近期取得一项新产品资质，获批产品为幽门螺杆菌抗原检测试剂盒（乳胶法），注册证号为国械注准20253402376，发证日期为2025年11月25日，有效期至2030年11月24日。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120100036897.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688253"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2585103404","title":"每周股票复盘：英诺特（688253）推股东回馈活动赠iPhone17等","url":"https://stock-news.laohu8.com/highlight/detail?id=2585103404","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2585103404?lang=zh_cn&edition=full","pubTime":"2025-11-23 02:49","pubTimestamp":1763837351,"startTime":"0","endTime":"0","summary":"截至2025年11月21日收盘，英诺特报收于30.49元，较上周的35.05元下跌13.01%。本周，英诺特11月17日盘中最高价报35.78元。英诺特当前最新总市值41.77亿元，在医疗器械板块市值排名77/126，在两市A股市值排名3692/5167。本周关注点公司公告汇总：英诺特联合同花顺开展股东回馈活动，奖品含iPhone 17 Pro Max、大疆无人机及自产检测试剂盒。报名后经身份认证，于12月1日开奖，中奖者需在12月10日前填写邮寄信息。本次活动为自愿性信息披露，不影响公司经营。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025112300000653.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688253","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2583654862","title":"每周股票复盘：英诺特（688253）Q3呼吸道产品仍为主要收入来源","url":"https://stock-news.laohu8.com/highlight/detail?id=2583654862","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2583654862?lang=zh_cn&edition=full","pubTime":"2025-11-16 04:18","pubTimestamp":1763237895,"startTime":"0","endTime":"0","summary":"截至2025年11月14日收盘，英诺特报收于35.05元，较上周的34.35元上涨2.04%。本周，英诺特11月10日盘中最高价报36.4元。英诺特当前最新总市值48.01亿元，在医疗器械板块市值排名76/126，在两市A股市值排名3482/5165。来自机构调研要点：2025年Q3毛利率与净利率同比下滑，主要受流行病趋势及税收政策影响。2025年第三季度，呼吸道病原体检测相关产品营业收入仍是公司营业收入主要组成部分，相关产品营业收入及增速与公司整体营业收入趋势基本一致。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025111600001188.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688253","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2580393417","title":"英诺特（688253）2025年三季报简析：净利润同比下降46.37%，三费占比上升明显","url":"https://stock-news.laohu8.com/highlight/detail?id=2580393417","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2580393417?lang=zh_cn&edition=full","pubTime":"2025-11-01 06:49","pubTimestamp":1761950972,"startTime":"0","endTime":"0","summary":"据证券之星公开数据整理，近期英诺特发布2025年三季报。截至本报告期末，公司营业总收入3.3亿元，同比下降36.56%，归母净利润1.31亿元，同比下降46.37%。按单季度数据看，第三季度营业总收入5396.95万元，同比下降45.9%，第三季度归母净利润611.8万元，同比下降84.04%。本报告期英诺特三费占比上升明显，财务费用、销售费用和管理费用总和占总营收同比增幅达37.3%。去年的净利率为39.73%，算上全部成本后，公司产品或服务的附加值极高。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025110100007870.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688253"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2579109281","title":"股市必读：英诺特三季报 - 第三季度单季净利润同比下降84.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579109281","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579109281?lang=zh_cn&edition=full","pubTime":"2025-10-31 06:29","pubTimestamp":1761863374,"startTime":"0","endTime":"0","summary":"业绩披露要点财务报告英诺特2025年三季报显示，前三季度实现营业收入3.3亿元，同比下降36.56%；归母净利润1.31亿元，同比下降46.37%；扣非净利润1.12亿元，同比下降49.96%。2025年第三季度单季度营业收入5396.95万元，同比下降45.9%；单季度归母净利润611.8万元，同比下降84.04%；单季度扣非净利润93.04万元，同比下降97.13%。归属于上市公司股东的净利润本报告期为611.80万元，同比下降84.04%；年初至报告期末为1.31亿元，同比下降46.37%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103100008279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688253"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2579611331","title":"英诺特(688253.SH)发布前三季度业绩，归母净利润1.31亿元，同比下降46.37%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579611331","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579611331?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:38","pubTimestamp":1761817131,"startTime":"0","endTime":"0","summary":"智通财经APP讯，英诺特(688253.SH)披露2025年第三季度报告，公司前三季度实现营收3.3亿元，同比下降36.56%;归母净利润1.31亿元，同比下降46.37%;扣非净利润1.12亿元，同比下降49.96%;基本每股收益0.96元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1362822.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"英诺特(688253.SH)发布前三季度业绩，归母净利润1.31亿元，同比下降46.37%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688253"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2579358118","title":"英诺特(688253)9月30日股东户数0.8万户，较上期增加10.57%","url":"https://stock-news.laohu8.com/highlight/detail?id=2579358118","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2579358118?lang=zh_cn&edition=full","pubTime":"2025-10-30 17:28","pubTimestamp":1761816521,"startTime":"0","endTime":"0","summary":"证券之星消息，近日英诺特披露，截至2025年9月30日公司股东户数为8037.0户，较6月30日增加768.0户，增幅为10.57%。在医疗器械行业个股中，英诺特股东户数低于行业平均水平，截至9月30日，医疗器械行业平均股东户数为2.21万户。从股价来看，2025年6月30日至2025年9月30日，英诺特区间跌幅为0.36%，在此期间股东户数增加768.0户，增幅为10.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025103000033150.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688253"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2570891742","title":"每周股票复盘：英诺特（688253）限制性股票归属526,120股上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2570891742","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2570891742?lang=zh_cn&edition=full","pubTime":"2025-09-28 03:32","pubTimestamp":1759001534,"startTime":"0","endTime":"0","summary":"截至2025年9月26日收盘，英诺特报收于31.12元，较上周的30.9元上涨0.71%。公司公告汇总北京英诺特生物技术股份有限公司完成2023年限制性股票激励计划首次授予部分第二个归属期及预留授予部分第一个归属期的股份登记。本次归属合计76人，其中首次授予57人，预留授予19人，共归属526,120股，来源为公司向激励对象定向发行A股普通股。上市流通日为2025年9月30日，上市流通数量为526,120股。本次归属后公司总股本由136,458,196股增至136,984,316股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025092800000818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688253"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1775240294171,"stockEarnings":[{"period":"1week","weight":-0.0373},{"period":"1month","weight":0.0483},{"period":"3month","weight":0.164},{"period":"6month","weight":0.1424},{"period":"1year","weight":-0.0115},{"period":"ytd","weight":0.164}],"compareEarnings":[{"period":"1week","weight":-0.0086},{"period":"1month","weight":-0.0496},{"period":"3month","weight":-0.0224},{"period":"6month","weight":-0.0007},{"period":"1year","weight":0.161},{"period":"ytd","weight":-0.0224}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"北京英诺特生物技术股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"8037人(较上一季度增加10.57%)","perCapita":"17044股","listingDate":"2022-07-28","address":"北京市丰台区海鹰路1号院6号楼1层2层","registeredCapital":"13698万元","survey":" 北京英诺特生物技术股份有限公司的主营业务是POCT快速诊断产品研发、生产和销售。公司的主要产品是呼吸道系列、优生优育系列、其他试剂系列、POCT诊断仪器。","listedPrice":26.06},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.39.0","shortVersion":"4.39.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"英诺特(688253)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供英诺特(688253)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"英诺特,688253,英诺特股票,英诺特股票老虎,英诺特股票老虎国际,英诺特行情,英诺特股票行情,英诺特股价,英诺特股市,英诺特股票价格,英诺特股票交易,英诺特股票购买,英诺特股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"英诺特(688253)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供英诺特(688253)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}